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Abstract
Background:  Antipyretic drugs are widely used in children with fever, though there is a
controversy about the benefit of reducing fever in children with malaria. In order to assess the
effect of ibuprofen on fever compared to placebo in children with uncomplicated Plasmodium
falciparum malaria in Gabon, a randomized double blind placebo controlled trial, was designed.
Methods: Fifty children between two and seven years of age with uncomplicated malaria were
included in the study. For the treatment of fever, all patients "received" mechanical treatment when
the temperature rose above 37.5°C. In addition to the mechanical treatment, continuous fanning
and cooling blanket, patients were assigned randomly to receive ibuprofen (7 mg/kg body weight,
every eight hours) or placebo.
Results: The fever clearance time using a fever threshold of 37.5°C was similar in children
receiving ibuprofen compared to those receiving placebo. The difference was also not statistically
significant using a fever threshold of 37.8°C or 38.0°C. However, the fever time and the area under
the fever curve were significantly smaller in the ibuprofen group compared to the placebo group.
Conclusion: Ibuprofen is effective in reducing the time with fever. The effect on fever clearance
is less obvious and depends on definition of the fever threshold.
Trial registration: The trial registration number is: NCT00167713
Background
Fever represents the most apparent clinical manifestation
of  Plasmodium falciparum malaria. The role of fever in
defence against malaria or in other infectious diseases
remains a matter of debate. However, it has been shown
that febrile temperatures inhibit the growth of P. falci-
parum in vitro [1,2].
To control fever, the World Health Organization recom-
mends mechanical measures such as fanning, tepid
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spoging, and cooling blankets [3]. However, antipyretic
drugs are commonly and widely used to treat malarial
fever in endemic areas, though there is a controversy
about the benefit of reducing fever in children with
malaria [4]. Data from Gabon have revealed that neither
paracetamol, nor naproxen or metamizol – antipyretics
often used in this area – had an effect on fever clearance
time [5,6]. Naproxen showed a weak effect in reducing
fever peaks and in reducing the time spent with fever [6].
Worryingly, paracetamol increased parasite-clearance
times (i.e. inhibited clearance of parasites) and signifi-
cantly decreased the production of oxygen radicals and
tumor necrosis factor, mechanisms of the innate immune
response pivotal to combat infections [5].
Another antipyretic drug often used to treat malarial fever
in endemic areas is the non-steroidal anti-inflammatory
agent ibuprofen. In various studies, ibuprofen has been
shown to be more efficacious than acetaminophen (para-
cetamol) in lowering febrile temperatures of infectious
origin in children [7-11]. But the rationale of its use and
its capacity of reducing fever due to P. falciparum malaria
has never been proven in a double blind, placebo control-
led trial. In a randomized, double-blind study in Thai
adults, comparing a single dose of ibuprofen with para-
cetamol for the treatment of fever due to uncomplicated
falciparum malaria, ibuprofen was significantly more
effective than paracetamol in lowering temperatures
throughout the first 4.5 h after dosing [12], whereas in
Malawian children aged less than five years both drugs
were equally effective in reducing fever [13].
In this double-blind randomized controlled trial, the
effect of ibuprofen on fever compared to placebo in chil-




The study was conducted at the Medical Research Unit of
the Albert Schweitzer Hospital in Lambaréné, Gabon.
Malaria is hyperendemic in this area with perennial trans-
mission and an entomological inoculation rate of about
50 infective bites/person/year [14,15].
Eligibility criteria
Hospitalized pediatric patients (male and female) with
clinically uncomplicated falciparum malaria were
included in the study. The inclusion criteria were: two to
seven years of age, asexual parasitaemia between 20,000
and 200,000/µL, no mixed plasmodial infection, fever
with temperature above 38°C or history of fever during
the preceding 24 hours, informed consent by parents or
guardians. The exclusion criteria were: effective anti-
malarial treatment for the present attack (negative urine
tests for chloroquine, quinine and sulphonamides (Wil-
son and Edeson tests, Lignin test)), antipyretic use within
six hours of presentation, contraindications to the use of
ibuprofen (history of asthma, dyspeptic symptoms, gas-
tro-intestinal bleeding, or allergy to ibuprofen), haemo-
globin < 7 g/dl, packed-cell volume < 20%, white cell
count > 16,000/µL, platelet count < 40,000/µL, schizon-
taemia > 50/µL, impaired consciousness, convulsions or
history of convulsions, concomitant diseases masking
assessment of response.
Interventions
Patients were hospitalized until two consecutive thick
blood smears were negative for malaria parasites. For
malaria treatment, all patients received an infusion of 250
mL of 5% glucose with 12 mg/kg of quinine dihydrochlo-
ride every 12 h for 72 h, then a single dose of oral sul-
phadoxine/pyrimethamine (500 mg/25 mg tablet) was
given according to weight category (body weight ≤ 10.0
kg: 0.25 tablet; 10.1–14.0 kg: 0.5 tablet; 14.1–20.0 kg: 1.0
tablet; 20.1–30.0 kg: 1.5 tablets) after the last infusion.
This regimen has been found to be efficacious in the study
area [16].
For the treatment of fever, all patients received mechanical
treatment (continuous fanning and cooling blanket)
when the temperature rose above 37.5°C. In addition to
the mechanical treatment, patient were assigned ran-
domly to receive ibuprofen or placebo. Ibuprofen was
provided as syrup of Nurofen® (Boots Healthcare Interna-
tional, Nottingham, UK), 5 mL of syrup Nurofen® con-
taining 100 mg of ibuprofen. The dosage was 7 mg/kg 8
hourly until fever and parasite clearance. Placebo, identi-
cal to the test drug in colour, smell and packaging, was
given every 8 hours until fever and parasite clearance. The
drugs were administered under supervision. In the event
of vomiting within one hour of drug ingestion, the dose
was immediately re-administered. Placebo was provided
by the University Pharmacy, University of Tübingen,
Tübingen, Germany.
Study design
The study was designed as a double blind, placebo con-
trolled study to compare the antipyretic efficacy of ibupro-
fen versus placebo in children with uncomplicated
falciparum malaria.
Outcome measures
The study primary endpoint was the fever clearance time
(FCT) in hours at a fever threshold of 37.5°C. The Fever
time (FT) and the Area Under the Curve with fever (AUCfe-
ver) were used as supportive primary efficacy endpoints.
The following definitions for efficacy measures were used:Malaria Journal 2008, 7:91 http://www.malariajournal.com/content/7/1/91
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- Fever clearance times: time from the start of ibuprofen or
placebo therapy to the time that the temperature fell
below and remained less or equal 37.5°C and remained
at ≤ 37.5°C until parasite clearance (two consecutive neg-
ative thick blood smears for asexual P. falciparum). The
FCT was also calculated for fever thresholds of 37.8°C and
38.0°C.
- Fever time: duration in hours that an individual's tem-
perature was above an indicated fever threshold.
- Area Under the Curve with fever: area covered by the
temperatures' curve during the hospitalization period
(area between the temperatures' curves and an horizontal
line which represents different fever thresholds).
The following approaches have been used for the calcula-
tion of the FCT and FT: i) a temperature elevations more
than 12 hours after parasite clearance were not consid-
ered; ii) if at least 12 consecutive temperature values were
missing, the patient was considered not evaluable; iii) in
the case that no fever was present at baseline and through-
out the hospitalization period, the FCT equaled zero.
The secondary endpoints were: i) parasite clearance times,
calculated from the beginning of antipyretic treatment to
the time of the first of two consecutive negative films for
asexual parasites; ii) assessment of adverse events. An
adverse event was defined as any sign or symptom that
appears or that increases in intensity after the beginning of
the antipyretic treatment. A serious adverse event was
defined as any untoward medical occurrence that is life
threatening or that requires prolongation of hospitaliza-
tion. The study physicians recorded all adverse events and
classified them according to their seriousness, intensity,
and causality.
Digital thermometers were used to measure rectal temper-
ature on admission and every hour for the duration of the
hospitalization period. Blood smears for parasitaemia
were taken at the time of admission and every 8 hours
until two consecutive blood smears were negative for
asexual P. falciparum. The parasitaemia was determined, as
described previously [17], from 10 µL of capillary blood
distributed evenly over an area of 18 × 10 mm on a glass
slide and prepared as a Giemsa-stained thick smear. The
number of parasites per 100 oil-immersion fields
(1,000×) was counted and multiplied by 600 (using an
Olympus CH30 microscope) to calculate the number of
parasites per µL of blood. Each blood film was read inde-
pendently by two experienced laboratory technicians.
Physical examination was done prior to treatment and
once daily until discharge, and symptom histories was
obtained every eight hours. Blood for haematology (hae-
moglobin, haematocrit, total and differential white cell
count and platelet count) was obtained prior to treatment
and at the time of discharge.
Sample size
Sample size calculation was based on fever clearance time
(FCT). The difference in mean FCT between the two
groups (ibuprofen versus placebo) was estimated from
previous studies [5,6]. The sample size was calculated on
the assumption of difference in FCT of 15 h between the
two groups with standard deviation (SD) of mean FCT of
15 h at a significance level of 5% and a power of 90%. The
estimated number of patients needed per group was 22.
To allow for patient loss and non evaluable patients 25
patients were included in each group. A total of 50
patients were included.
Randomization procedures
The patients were allocated by the study physicians to ibu-
profen or placebo in the order of admission according to
a computer generated randomization list. All study per-
sonnel and participants were blinded to treatment assign-
ment for the duration of the study (double blind design).
The code was contained in sealed envelopes, each with the
study number writing on the outside. The code was kept
in a locked cupboard in the hospital in Lambaréné and
only the principal investigator and one subinvestigator
had direct access to the key. A second set of the code was
kept by the University Pharmacy, Tübingen, Germany)
where the placebos were manufactured. The code was
shown to the investigators once recruitment, laboratory
analyses, data collection and data cleaning were complete.
Statistical methods
Descriptive statistics were used to summarize the baseline
data. The analysis for the primary endpoint was per proto-
col analysis and was based on all evaluable patients. The
safety analysis included adverse events from all subjects
who received at least one dose of the study drug (inten-
tion-to-treat population). Differences between treatment
groups were assessed by student t-test. The Area Under the
Curve for fever was calculated by use of the trapezoid rule
and performed using JMP software (Version 5, SAS Insti-
tute, USA). P-values of less than 0.05 were considered sig-
nificant.
Ethical aspects
Informed consent procedures, documentation and clini-
cal activities followed Good Clinical Practice guidelines.
The ethics committee of the International Foundation of
the Albert Schweitzer Hospital in Lambaréné approved
the study and informed consent was obtained from each
participant's parent or guardian before any study specific
procedure was started.Malaria Journal 2008, 7:91 http://www.malariajournal.com/content/7/1/91
Page 4 of 8
(page number not for citation purposes)
Trial registration
The present study was registered on 11th September 2005
on the following online registry: clinicaltrials.gov The reg-
istration number is: NCT00167713.
Results
Between April 2003 and January 2004, 1230 children
were prescreened for malaria and 430 had a positive
blood smear (Figure 1). Fifty children met the inclusion
criteria and were randomly assigned to treatment and
were analysed. Table 1 shows the baseline characteristics
of the patients.
Forty-nine patients were hospitalized until fever clearance
and two consecutive negative blood smears for malaria
parasites. One patient, receiving ibuprofen, had convul-
sions 12 h after the start of the antipyretic and quinine
treatment, and was excluded from the study. Two chil-
dren, both in the ibuprofen group, were excluded for pro-
tocol violation: one for axillary temperature
measurement, one for consecutive missing temperature
values for 24 hours. Forty-seven children (22 in the ibu-
profen group and 25 in the placebo group) completed the
study protocol and were analysed for the primary out-
come (fever clearance time).
The two groups were similar with respect to baseline char-
acteristics (Table 1).
Patients were hospitalized for a mean (± SD) of 80.0 h (±
10.0) vs. 79.0 h (± 11.0) for ibuprofen and placebo,
respectively. Overall, the FCT was significantly lower than
the PCT (47.0 h (± 23) vs. 66.0 h (± 15), respectively, p <
0.001).
In Table 2, the two groups are compared with respect to
FCT, FT, and AUCfever at different fever tresholds. The FCT
at fever threshold of 37.5°C was lower in children receiv-
ing ibuprofen in addition to the mechanical treatment
(41.0 h ± 21) than in those receiving only mechanical
treatment (placebo group) (52.0 h ± 24); however, this
difference was not significant. Similar results were found
for FCT using a fever threshold of 37.8°C (37.0 h ± 21 vs.
44 h ± 24, for ibuprofen and placebo, respectively). Simi-
larily, the difference in the FCT between the two groups
using a fever threshold of 38.0 was also not statistically
significant (29.0 h ± 23 vs. 41 h ± 22, for ibuprofen and
placebo, respectively). However, the measurements of
fever time (FT) at different fever thresholds showed that
children in ibuprofen group spent significantly less time
with fever compared to children in placebo group. Like-
wise, the AUCfever were also significantly lower for the ibu-
profen group compared to the placebo group over a wide
range of fever thresholds (Table 2). There was no differ-
ence in parasite clearance time between the two groups.
Data on all 50 patients were available for the intention-to-
treat analysis. There was no significant difference between
the two groups in the proportion of patients experiencing
any adverse event: seven out of 25 (28%) versus nine out
25 (36%) patients had at least one adverse event in ibu-
profen and placebo groups, respectively. One of the
adverse events (convulsions 12 h after admission in a
child receiving ibuprofen) was classified as a serious
adverse event and not due to the study medication. The
others were classified as mild or moderate in intensity,
unlikely to be due to the study drug. These included vom-
iting, headache, abdominal pain, fatigue, diarrhea, cough,
fever, and conjunctivitis.
Discussion
This study demonstrated that ibuprofen is effective in
reducing the time that a child with malaria is exposed to
febrile body temperatures. The effect on fever clearance is
less obvious and depends on the definition of the fever
threshold. This study failed to show a significant effect of
ibuprofen in clearing fever in malaria. However, it does
demonstrate that the drug is effective in reducing the time
that a child is exposed to febrile body temperatures. This
difference is due to the fact that the effect of ibuprofen on
body temperature lies in the reduction of high fever peaks.
In this context, the term "fever peak" signifies elevated
temperatures over a period of time, rather that just a tem-
perature maximum.
This study also demonstrated that the area under the fever
curve was significantly smaller for children who took ibu-
profen compared to those who took placebo. Ibuprofen
can reduce the "burden" of fever during malaria. This may
procure some kind of comfort to the child. However, it is
recognized that the assessment of the child's comfort may
be difficult.
Previous studies from Gabon have shown that neither
paracetamol nor metamizol had an effect on fever clear-
ance time compared to mechanical methods [5,6].
Naproxen, which is closely related to ibuprofen, both
belonging to the propionic acid group, had a small effect
on fever clearance time and could reduce fever peaks [6]
as observed in the present study with ibuprofen. Com-
pared to paracetamol, ibuprofen has been shown to be
more efficacious for the treatment of fever with infectious
diseases in children [7-11]. Studies comparing the two
drugs in malaria showed conflicting results: Ibuprofen
was shown to be more effective in Thai adults [12], but
equally effective in Malawian children [13].
The use of antipyretics in febrile children remains contro-
versial. For the comfort of the child and, most of the time,
to satisfy parents' requests, physicians or other health care
professionnels are often obliged to prescribe antipyreticMalaria Journal 2008, 7:91 http://www.malariajournal.com/content/7/1/91
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treatments to combat fever, although there is no evidence
of the therapeutic benefit of this treatment. Moreover, it
has been shown that fever may be beneficial for the
patient [18]. A number of animal studies have shown var-
ious beneficial effects of fever: the survival value of fever
in the desert iguana infected with Aeromonas hydrophila
and the harmful effect of antipyretic treatment in the same
animals have been demonstrated. [19,20].
In vitro studies have indicated that a variety of human
immunological defence mechanisms function better at
febrile temperatures than at normal ones [21]. Inter-
leukin-1 (IL-1) and other endogenous pyrogens have a
number of direct effects on the immune response includ-
ing B-lymphocyte proliferation and antibody production,
T-lymphocyte activation, helper T-lymphocyte prolifera-
tion, enhanced T-lymphocyte cell killing, and interferon
production and function. But, despite the enhanced
immune function that occurs at febrile temperatures,
Table 1: Clinical, parasitological, and laboratory characteristics on admission
Ibuprofen (n = 25) Placebo (n = 25)
Patients' data
Gender (F/M) 10/15 8/17
Age (years) 3.6 ± 1.4 4.5 ± 1.7
Temperature * (°C) 38.1 ± 1.0 38.7 ± 1.1
Laboratory data
Geometric mean parasitemia (range) 63,557 (20,000 – 200,000) 70,516 (20,000 – 200,000)
Hemoglobin (g/dL) 9.3 ± 1.2 9.6 ± 1.3
Packed-cell volume (%) 28.8 ± 4.2 29.6 ± 4.2
Leucocytes count (/µL) 7,400 ± 3,400 7.9 ± 2,300
Platelets (/µL) 157,000 ± 63,000 141,000 ± 43,000
Data were summarized by use of descriptive statistics.
Numbers are given as mean ± SD, unless specified otherwise.
* N = 49 (one patient in ibuprofen group was excluded because axillary temperature was recorded)
Table 2: Fever clearance time, fever time, and the area under the curve at different fever threshold in the two treatment groups
Fever threshold (°C) Ibuprofen N = 22 Placebo N = 25 Difference1 (95% CI) P value2
FCT3, mean (SD) 37.5 41.0 (21.0) 52.0 (24.0) 11.0 (-2.2 – 24.1) 0.102
37.8 37.0 (21.0) 44.0 (24.1) 7.0 (-6.4 – 20.0) 0.307
38.0 29.0 (23.0) 41.0 (22.3) 12.0 (-0.9 – 25.5) 0.067
FT4, mean (SD) 37.5 18.3 (15.5) 28.0 (16.0) 9.7 (0.5 – 19.0) 0.040
37.8 13.4 (13.4) 22.6 (13.1) 9.2 (1.4 – 17.0) 0.022
38.0 11.4 (11.9) 19.9 (11.5) 8.5 (1.6 – 15.3) 0.017
38.5 7.4 (8.5) 13.0 (9.1) 5.7 (0.5 – 10.9) 0.032
39.0 4.2 (5.2) 9.1 (7.8) 4.8 (0.9 – 8.7) 0.018
39.5 1.8 (2.6) 6.0 (6.6) 4.2 (1.2 – 7.2) 0.007
40.0 0.2 (0.4) 2.5 (3.9) 2.3 (0.7 – 4.0) 0.007
AUCfever
5, mean (SD) 37.5 16.6 (17.3) 31.9 (21.0) 15.3 (3.9 – 26.7) 0.010
37.8 11.9 (13.2) 24.4 (17.4) 12.5 (3.3 – 21.6) 0.009
38.0 9.4 (10.8) 20.1 (15.3) 10.7 (2.8 – 18.6) 0.009
38.5 4.8 (5.9) 12.1 (11.0) 7.3 (2.0 – 12.6) 0.008
39.0 2.0 (2.6) 6.7 (7.2) 4.7 (1.4 – 8.0) 0.006
39.5 0.5 (0.8) 2.9 (3.9) 2.5 (0.7 – 4.2) 0.006
40.0 0.03 (0.1) 0.8 (1.6) 0.8 (0.1 – 1.4) 0.026
1The mean differences between treatment groups were assessed by student t-test.
2P-values of less than 0.05 were considered significant.
3FCT (in hour): Fever clearance time (The time from the commencement of ibuprofen or placebo therapy to the time that the temperature fell 
below and remained less or equal a determined fever threshold until parasite clearance).
SD: standard deviation
4FT (in hour): fever time (the time spent at a temperature equal or superior to a determined fever threshold)
5AUCfever (in °C.hour): Area under the curve with fever (the area covered by a temperature curve at a determined fever threshold).
The AUCfever was calculated by use of the trapezoid rule.Malaria Journal 2008, 7:91 http://www.malariajournal.com/content/7/1/91
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studies in humans have not convincingly demonstrated
common clinically important risks with the use of antipy-
retic therapy in common viral and bacterial infections.
However, rare serious adverse events occurring after intake
of antipyretics remain a concern.
Prevention of "febrile convulsion" is also one of the rea-
sons for a systematic treatment of fever in children. How-
ever, there is no evidence to show that antipyretics
treatment reduce the risk of febrile convulsion [22-25].
Furthermore, it is likely that not the fever itself, but the
systemic pathophysiological changes during infections
can induce convulsions [26], fever being only a confound-
ing factor in this relationship. Taken the case of P. falci-
parum  malaria as an example, more than half of all
convulsions occur at a time point when the children do
not have fever (rectal temperature < 38.0°C) [26,27].
Thus, the concept of "febrile convulsions" is questionable.
Recent sudies have demonstrated that cellular activation
and the consequent release of an inflammatory cytokine
cascade may play a role in the pathogenesis of febrile sei-
zures [28,29].
In this study there was no difference in parasite clearance
time between the ibuprofen and the placebo group,
whereas one might expect a prolonged PCT in the group
receiving ibuprofen. This has been shown in previous in
vivo study, in which paracetamol prolonged parasite
clearance time [5] and in an in-vitro study which showed
a strong growth inhibition of P. falciparum at 40°C [1].
The present study confirms the results of previous studies
in this area, which have shown that antipyretic drugs com-
monly used (paracetamol, metamizol and naproxen)
have no significant effect on fever clearance time. How-
ever propionic acid compounds have an effect in reducing
fever peaks and reducing the time that a child spends with
fever during malaria. This raises questions about the use-
fulness of antipyretics in children with malaria and other
infectious diseases, bearing in mind that all antipyretics
even in correct doses can induce serious adverse events, in
rare cases even fatal adverse events. Additionally, there is
a high risk of over dosing [30]. Moreover the cost for pro-
longed antipyretic treatment may be substantial for poor
families.
Therefore, antipyretics should not be given automatically
to all children with fever. Emphasis on the cause rather
than the effect of the fever will promote an efficient use of
health service and household resources targeted at chil-
dren who are likely to benefit, and will promote better
compliance with essential treatments.
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